Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 19/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 17/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600260 | 1.00 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL14538873 | 1.00 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296874 | 1.00 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296838 | 1.00 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7459932 | 0.97 | ADORA3 (0.64) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13296837 | 0.97 | ADORA3 (0.64) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13314999 | 0.95 | ADORA3 (0.62) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2167644 | 0.95 | ADORA3 (0.62) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2167641 | 0.95 | ADORA3 (0.62) | ADORA3ADORA2AADORA1ADORA2B | |
| Fumaric Acid SCHEMBL2709272 | 0.94 | ADORA3 (0.61) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756120-B1 | Purine derivative | GLAXO GROUP LTD (GB) | 2012-05-02 | — | — | EP | claimed |
| US-20080132526-A1 | Purine Derivative | GLAXO GROUP LIMITED (GB) | 2008-06-05 | — | — | US | claimed |
| EP-1756120-B1 | Purine derivative | GLAXO GROUP LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-7989629-B2 | 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl)-1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as H1 and H3 receptor antagonists for the treatment of inflammatory and/or allergic disorders | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7737126-B2 | Purine derivative | GLAXO GROUP LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-7737126-B2 | Purine derivative | GLAXO GROUP LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-7737126-B2 | Purine derivative | GLAXO GROUP LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| EP-2157087-A1 | 3-(4-{[4-(4-{[3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYL]OXY}PHENYL)-1-PIPERIDINYL]CARBONYL}-1-NAPHTHALENYL)PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-1963307-B1 | 3- (4- { [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL[0XY] PHENYL) -1-PIPERIDINYL CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LTD (GB) | 2009-11-25 | — | — | EP | disclosed |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080132526-A1 | Purine Derivative | GLAXO GROUP LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132526-A1 | Purine Derivative | GLAXO GROUP LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132526-A1 | Purine Derivative | GLAXO GROUP LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132526-A1 | Purine Derivative | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | HRH3, HRH1, HRH2 | ADORA3 193/4885ADORA2A 546/4885ADORA1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.